Clinical Trial Update: Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate [Phase 1]

View source ↗

Summary

A Phase 1 trial tested dasatinib with cyclosporine in chronic myeloid leukemia patients refractory or intolerant to imatinib. The study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• CYCLOSPORINE (cyclosporine)
• DASATINIB (Dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Status: TERMINATED